Semper Amanda E, Olver Janie, Warner Jenny, Cehovin Ana, Fay Petra C, Hart Peter J, Golding Josephine P, Benassi Virginia, Preziosi Marie-Pierre, Al-Asadi Khdair Hazbar Razzaq, Blumberg Lucille H, de la Fuente José, Elaldi Nazif, Fletcher Tom, Formenty Pierre B H, Gouya Mohammad Mehdi, Günther Stephan, Hewson Roger, Jamil Bushra, Kobinger Gary, Korukluoglu Gülay, Lempereur Laetitia, Palacios Gustavo, Papa Anna, Pshenichnaya Natalia, Schmaljohn Connie, Sow Samba O, Sprong Hein, Vatansever Zati, Brooks Timothy J G
Epidemic and Emerging Infections Group, UK Health Security Agency, Salisbury, UK.
Epidemic and Emerging Infections Group, UK Health Security Agency, Salisbury, UK.
Lancet Infect Dis. 2025 Apr;25(4):e223-e234. doi: 10.1016/S1473-3099(24)00656-X. Epub 2024 Nov 7.
Crimean-Congo haemorrhagic fever (CCHF) is a widely distributed and potentially fatal tick-borne viral disease with no licensed specific treatments or vaccines. In 2019, WHO published an advanced draft of a research and development roadmap for CCHF that prioritised the development and deployment of the medical countermeasures most needed by CCHF-affected countries. This Personal View presents updated CCHF research and development priorities and is the product of broad consultation with a working group of 20 leading experts in 2023-24. The strategic goals, milestones, and timelines have been revised and expanded to reflect scientific advances since 2019, including the identification of antibodies with therapeutic potential and the progression of four vaccine candidates through phase 1 clinical trials. This update emphasises the need for a One Health approach to manage CCHF, from integrated cross-sectoral surveillance to novel interventions that target ticks and their vertebrate hosts to reduce CCHF virus transmission to humans. The overarching vision for rapid diagnostics and specific therapeutics by 2028, followed by options to limit CCHF virus transmission and control disease by 2030, is deliberately ambitious and will only be achieved through coordinated international action from affected countries, funders, scientists, product developers, manufacturers, regulators, national authorities, and policy makers.
克里米亚-刚果出血热（CCHF）是一种广泛传播且可能致命的蜱传病毒性疾病，目前尚无获批的特效治疗方法或疫苗。2019年，世界卫生组织发布了一份CCHF研发路线图的预稿，该路线图优先考虑了受CCHF影响国家最急需的医疗对策的开发和部署。本个人观点阐述了更新后的CCHF研发重点，是在2023年至2024年期间与20位顶尖专家组成的工作组进行广泛磋商的成果。战略目标、里程碑和时间表已进行修订和扩展，以反映自2019年以来的科学进展，包括发现具有治疗潜力的抗体以及四种候选疫苗进入1期临床试验阶段。此次更新强调了采取“同一健康”方法来管理CCHF的必要性，从综合跨部门监测到针对蜱及其脊椎动物宿主的新型干预措施，以减少CCHF病毒向人类的传播。到2028年实现快速诊断和特效治疗，随后到2030年采取措施限制CCHF病毒传播并控制疾病，这一总体愿景目标远大，只有通过受影响国家、资助者、科学家、产品开发者、制造商、监管机构、国家当局和政策制定者的协调国际行动才能实现。
